"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA Approves nivolumab (Opdivo) and ipilimumab (Yervoy) in combination for the treatment of advanced renal cell carcinoma

FDA Approves nivolumab (Opdivo) and ipilimumab (Yervoy) in combination for the treatment of advanced renal cell carcinoma

17 Apr 2018 1:52 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted approvals to nivolumab (Opdivo; Bristol-Myers Squibb) and ipilimumab (Yervoy; Bristol-Myers Squibb) in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software